These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7488426)

  • 21. Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
    Marshall D; Pedley RB; Boden JA; Boden R; Begent RH
    Br J Cancer; 1994 Mar; 69(3):502-7. PubMed ID: 8123481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased streptavidin uptake in tumors pretargeted with biotinylated antibody using a conjugate of streptavidin-fab fragment.
    Yao Z; Zhang M; Sakahara H; Saga T; Kobayashi H; Nakamoto Y; Toyama S; Konishi J
    Nucl Med Biol; 1998 Aug; 25(6):557-60. PubMed ID: 9751423
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity.
    Kobayashi H; Sato N; Saga T; Nakamoto Y; Ishimori T; Toyama S; Togashi K; Konishi J; Brechbiel MW
    Eur J Nucl Med; 2000 Sep; 27(9):1334-9. PubMed ID: 11007515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-specific detection of an optically targeted antibody combined with a quencher-conjugated neutravidin "quencher-chaser": a dual "quench and chase" strategy to improve target to nontarget ratios for molecular imaging of cancer.
    Ogawa M; Kosaka N; Choyke PL; Kobayashi H
    Bioconjug Chem; 2009 Jan; 20(1):147-54. PubMed ID: 19072537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
    Wilbur DS; Hamlin DK; Vessella RL; Stray JE; Buhler KR; Stayton PS; Klumb LA; Pathare PM; Weerawarna SA
    Bioconjug Chem; 1996; 7(6):689-702. PubMed ID: 8950488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin.
    Otsuji E; Yamaguchi T; Yamamoto K; Matsumura H; Tsuruta H; Yata Y; Nishi H; Okamoto K; Kitamura K; Takahashi T
    Jpn J Cancer Res; 1997 Feb; 88(2):205-12. PubMed ID: 9119750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localization of human osteogenic sarcoma xenografts in nude mice by a monoclonal antibody labeled with radioiodine and indium-111.
    Sakahara H; Endo K; Nakashima T; Koizumi M; Kunimatsu M; Kawamura Y; Ohta H; Nakamura T; Tanaka H; Kotoura Y
    J Nucl Med; 1987 Mar; 28(3):342-8. PubMed ID: 3469333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
    Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
    J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
    Frost SH; Bäck T; Chouin N; Jensen H; Hultborn R; Jacobsson L; Lindegren S
    Cancer Biother Radiopharm; 2011 Dec; 26(6):727-36. PubMed ID: 22087606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of radiochemical design of antibodies using an ester bond as the metabolizable linkage: evaluation of maleimidoethyl 3-(tri-n-butylstannyl)hippurate as a radioiodination reagent of antibodies for diagnostic and therapeutic applications.
    Arano Y; Wakisaka K; Ohmono Y; Uezono T; Akizawa H; Nakayama M; Sakahara H; Tanaka C; Konishi J; Yokoyama A
    Bioconjug Chem; 1996; 7(6):628-37. PubMed ID: 8950481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin.
    Paganelli G; Stella M; Zito F; Magnani P; De Nardi P; Mangili F; Baratti D; Veglia F; Di Carlo V; Siccardi AG
    J Nucl Med; 1994 Dec; 35(12):1970-5. PubMed ID: 7989979
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biodistribution of monoclonal antibody Po66 in a human lung tumour-bearing mouse model: effect of blood exchange on tumour antibody uptake.
    Desrues B; Quinquenel ML; Toujas L; Delaval P; Dazord L
    Nucl Med Biol; 1995 Jul; 22(5):569-72. PubMed ID: 7581165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improving tumor-to-normal-tissue ratios of antibodies by extracorporeal immunoadsorption based on the avidin-biotin concept: development of a new treatment strategy applied to monoclonal antibodies murine L6 and chimeric BR96.
    Tennvall J; Garkavij M; Chen J; Sjögren HO; Strand SE
    Cancer; 1997 Dec; 80(12 Suppl):2411-8. PubMed ID: 9406691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved intratumoral penetration of radiolabeled streptavidin in intraperitoneal tumors pretargeted with biotinylated antibody.
    Zhang M; Yao Z; Saga T; Sakahara H; Nakamoto Y; Sato N; Nakada H; Yamashina I; Konishi J
    J Nucl Med; 1998 Jan; 39(1):30-3. PubMed ID: 9443734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in rats.
    Wang Z; Garkavij M; Ohlsson T; Strand SE; Sjögren HO; Tennvall J
    Cancer Biother Radiopharm; 2003 Jun; 18(3):365-75. PubMed ID: 12954123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship between in vitro binding activity and in vivo tumor accumulation of radiolabeled monoclonal antibodies.
    Sakahara H; Endo K; Koizumi M; Nakashima T; Kunimatsu M; Watanabe Y; Kawamura Y; Nakamura T; Tanaka H; Kotoura Y
    J Nucl Med; 1988 Feb; 29(2):235-40. PubMed ID: 3162255
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-L-lysine as effector molecule.
    Frost SH; Jensen H; Lindegren S
    Cancer; 2010 Feb; 116(4 Suppl):1101-10. PubMed ID: 20127953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
    Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
    Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin.
    Otsuji E; Yamaguchi T; Matsumura H; Yamamoto K; Tsuruta H; Yata Y; Nishi H; Okamoto K; Kitamura K; Takahashi T
    Br J Cancer; 1996 Aug; 74(4):597-602. PubMed ID: 8761376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.